Article Information
History
- March 20, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Fritz Raisera,
- Matthew Davisb,
- Jeffrey Adelglassc,
- Miranda R. Caid,
- Gordon Chaud,
- Shane Cloney-Clarkd,
- Mark Eickhoffd,
- Raj Kalkerid,
- Irene McKnightd,
- Joyce Plestedd,
- Mingzhu Zhud,
- Lisa Dunkled,# and
- the 2019nCoV-307 study team*
- aMeridian Clinical Research, 3345 N 107th St, Omaha, NE 68134 USA
- bRochester Clinical Research, 500 Helendale Road, Suite L20, Rochester, NY 14609 USA
- cResearch Your Health, 6020 W. Parker Rd., Suite 305, Plano, TX 75093 USA
- dNovavax, Inc., 21 Firstfield Rd, Gaithersburg, MD 20878, USA
- ↵#Corresponding Author: Lisa M. Dunkle ldunkle{at}novavax.com Novavax Inc., 21 Firstfield Rd, Gaithersburg, MD 20878, USA
Posted March 20, 2023.
Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults
